Benzinga

Benzinga

Benzinga

lunes, agosto 24

Karyopharm Therapeutics Inc

KPTINASDAQ
Trade with Public
Trade with Public
$1.88
-0.08-4.08%
Últ. Act.: Aug 24, 10:23 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Karyopharm Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Karyopharm Therapeutics (KPTI).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingOutperform# Analysts7Avg. Consensus PT$16Upside to Avg. PT+774.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 31, 2026Piper SandlerEdward TenthoffPT CutOverweight$16→$7
Jul 31, 2026HC Wainwright & Co.Robert BurnsDowngradeBuy→Neutral$13→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.
Benzinga Newsdesk

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
Avi Kapoor

Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.
Avi Kapoor

This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
Avi Kapoor

This Edison International Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, initiations. Analysts have mixed views on EIX stock.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3

HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral and lowers the price target from $13 to $3.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved